A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

3상 진행 중(모집 완료) NCT03451851

요약

The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.

Part 1: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

At Week 16 · Percentages of participants

Part 1: Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16

At Week 16 · Percentage of Participants

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

• A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab i — UCB Biopharma SRL
• A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoria — Janssen Pharmaceutical K.K.
• A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoria — Janssen Research & Development, LLC
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects Wi — UCB Biopharma SRL
• A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With A — UCB Biopharma SRL
• The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis — Hangzhou Highlightll Pharmaceutical Co., Ltd

전체 임상